Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andy Christoforou

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Nature Communications|October 2, 2021
Spatiotemporal proteomic profiling of the pro-inflammatory response to lipopolysaccharide in the THP-1 human leukaemia cell lineClaire M Mulvey, Lisa M Breckels, Oliver M Crook, et al.
Methods in Molecular Biology (Clifton, N.J.)|August 22, 2013
Identification of protein biomarkers in human serum using iTRAQ and shotgun mass spectrometryTheodoros A Koutroukides, Julian A J Jaros, Bob Amess, et al.
Journal of Medicinal Chemistry|October 7, 2025
Discovery of Potent and Selective BCL6 Ligand-Directed Degrader (LDD), BCL6-760Hunter P Shunatona, Natalie Holmberg Douglas, Jayce Rhodes, et al.
Blood|June 29, 2026
NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple MyelomaBo Hu, Jacob Edwards, Hardik Modi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancerSurendra Nayak, John D Norris, Massimo Ammirante, et al.
Journal of Medicinal Chemistry|February 11, 2026
Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin LymphomaDeborah S Mortensen, Hunter P Shunatona, Natalie Holmberg-Douglas, et al.
Blood Cancer Discovery|November 3, 2025
Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell LymphomaZhongying Mo, Lynda Groocock, Scott Wood, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Nature Communications|October 2, 2021
Spatiotemporal proteomic profiling of the pro-inflammatory response to lipopolysaccharide in the THP-1 human leukaemia cell lineClaire M Mulvey, Lisa M Breckels, Oliver M Crook, et al.
Methods in Molecular Biology (Clifton, N.J.)|August 22, 2013
Identification of protein biomarkers in human serum using iTRAQ and shotgun mass spectrometryTheodoros A Koutroukides, Julian A J Jaros, Bob Amess, et al.
Journal of Medicinal Chemistry|October 7, 2025
Discovery of Potent and Selective BCL6 Ligand-Directed Degrader (LDD), BCL6-760Hunter P Shunatona, Natalie Holmberg Douglas, Jayce Rhodes, et al.
Blood|June 29, 2026
NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple MyelomaBo Hu, Jacob Edwards, Hardik Modi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancerSurendra Nayak, John D Norris, Massimo Ammirante, et al.
Journal of Medicinal Chemistry|February 11, 2026
Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin LymphomaDeborah S Mortensen, Hunter P Shunatona, Natalie Holmberg-Douglas, et al.
Blood Cancer Discovery|November 3, 2025
Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell LymphomaZhongying Mo, Lynda Groocock, Scott Wood, et al.
Pageof 2